Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model von Snelder, Nelleke, Hoefman, Sven, Garcia-Hernandez, Alberto, Onkels, Hartmut, Larsson, Tobias E., Bergmann, Kirsten R.

Volltext

Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease von Hoefman, Sven, Snelder, Nelleke, van Noort, Martijn, Garcia-Hernandez, Alberto, Onkels, Hartmut, Larsson, Tobias E., Bergmann, Kirsten R.

Volltext

The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P‐glycoprotein and CYP3A4 von Groenendaal, Dorien, Strabach, Gregory, Garcia‐Hernandez, Alberto, Kadokura, Takeshi, Heeringa, Marten, Mol, Roelof, Eltink, Charlotte, Onkels, Hartmut

Volltext

Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects von Kadokura, Takeshi, Kashiwa, Makoto, Groenendaal, Dorien, Heeringa, Marten, Mol, Roelof, Verheggen, Frank, Garcia-Hernandez, Alberto, Onkels, Hartmut

Volltext

Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin von Kadokura, Takeshi, Groenendaal, Dorien, Heeringa, Marten, Mol, Roelof, Verheggen, Frank, Garcia-Hernandez, Alberto, Onkels, Hartmut

Volltext

The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein von Groenendaal, Dorien, Strabach, Gregory, Garcia-Hernandez, Alberto, Kadokura, Takeshi, Heeringa, Marten, Mol, Roelof, Eltink, Charlotte, Onkels, Hartmut

Volltext